Administration of adenovirus encoding anti-CD20 antibody gene induces B-cell deletion and alleviates lupus in the BWF1 mouse model

International Immunopharmacology

Volumn 11, Issue 6, 2011, Pages 693-697

  Wang, Chao ^a   Wang, Mian ^b   Liu, Yuan ^a   Zeng, Ping ^a  

^a CHENGDU MILITARY GENERAL HOSPITAL   (China)

^b Second People's Hospital of Chengdu   (China)

Author keywords

Adenovirus; Anti CD20 antibody; B cells; Lupus

Indexed keywords

ADENOVIRUS VECTOR; CD20 ANTIBODY; DOUBLE STRANDED DNA ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DESIGN; GENE DELETION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; SURVIVAL TIME; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; ANIMALS; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; B-LYMPHOCYTES; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE DEPLETION; MICE; MICE, MUTANT STRAINS; PROTEINURIA; TRANSGENES;

EID: 79955864941     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2011.01.014     Document Type: Article

References (40)

1. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003;100:2610-5. (Pubitemid 36297546)
2. Singh RR. SLE: translating lessons from model systems to human disease. Trends Immunol 2005;26:572-9. (Pubitemid 41726444)
3. Croker JA, Kimberly RP. SLE: challenges and candidates in human disease. Trends Immunol 2005;26:580-6. (Pubitemid 41726445)
4. Diamanti AP, Rosado MM, Carsetti R, Valesini G. B cells in SLE: different biological drugs for different pathogenic mechanisms. Autoimmun Rev 2007;7:143-8. (Pubitemid 350116727)
5. Anolik JH. B cell biology and dysfunction in SLE. Bull NYU Hosp Jt Dis 2007;65:182-6. (Pubitemid 351412130)
6. Eisenberg R. Targeting B cells in SLE: the experience with rituximab treatment (anti-CD20). Endocr Metab Immune Disord Drug Targets 2006;6:345-50. (Pubitemid 44941922)
7. Robak E, Robak T. Monoclonal antibodies in the treatment of systemic lupus erythematosus. Curr Drug Targets 2009;10:26-37.
8. Liossis SN, Sfikakis PP. Costimulation blockade in the treatment of rheumatic diseases. BioDrugs 2004;18:95-102. (Pubitemid 38507892)
9. Eisenberg R, Albert D. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat Clin Pract Rheumatol 2006;2:20-7. (Pubitemid 43153645)
10. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994;15:450-4. (Pubitemid 24272191)
11. Riley JK, Sliwkowski MX. CD20: a gene in search of a function. Semin Oncol 2000;27:17-24.
12. Uchida J, Lee Y, Hasegawa M, Liang Y, Bradney A, Oliver JA, et al. Mouse CD20 expression and function. Int Immunol 2004;16:119-29. (Pubitemid 38054633)
13. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001;40:205-11.
14. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003;48:1484-92. (Pubitemid 36682354)
15. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, et al. IDECC2B8: results of a phase I multiple-dose trial in patients with relapsed non- Hodgkin's lymphoma. J Clin Oncol 1997;15:3266-74. (Pubitemid 27419340)
16. Berinstein NL, Grillo-Lopez AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998;9:995-1001. (Pubitemid 28496709)
17. Fang J, Qian JJ, Yi S, Harding TC, Tu GH, VanRoey M, et al. Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 2005;23:584-90. (Pubitemid 41724897)
18. Marin M, Pelegrin-Zurilla M, Bachrach E, Noel D, Brockly F, Piechaczyk M. Antiviral activity of an intracellularly expressed single-chain antibody fragment directed against themurine leukemia virus capsid protein. Hum Gene Ther 2000;11:389-401. (Pubitemid 30101949)
19. Pelegrin M, Marin M, Noel D, Piechaczyk M. Genetically engineered antibodies in gene transfer and gene therapy. Hum Gene Ther 1998;9:2165-75. (Pubitemid 28498003)
20. Noel D, Pelegrin M, Marin M, Biard-Piechaczyk M, Ourlin JC, Mani JC, et al. In vitro and in vivo secretion of cloned antibodies by genetically modified myogenic cells. Hum Gene Ther 1997;8:1219-29.
21. Fairhurst AM, Wandstrat AE, Wakeland EK. Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease. Adv Immunol 2006;92:1-69. (Pubitemid 44828118)
22. Cohen-Solal JF, Jeganathan V, Hill L, Kawabata D, Rodriguez-Pinto D, Grimaldi C, et al. Hormonal regulation of B-cell function and systemic lupus erythematosus. Lupus 2008;17:528-32. (Pubitemid 351955427)
23. Clarke SH. Anti-Sm B cell tolerance and tolerance loss in systemic lupus erythematosus. Immunol Res 2008;41:203-16.
24. Monneaux F, Muller S. Peptide-based therapy in lupus: promising data. Adv Exp Med Biol 2007;601:105-12.
25. Waite L, Morrison E. Severe gastrointestinal involvement in systemic lupus erythematosus treated with rituximab and cyclophosphamide (B-cell depletion therapy). Lupus 2007;16:841-2. (Pubitemid 350069801)
26. Daugas E. Treatment of proliferative glomerulonephritis of systemic lupus erythematosus. Recent development and current recommendations. Rev Méd Interne 2008;29:710-7.
27. Takiguchi M, Murakami M, Nakagawa I, Yamada A, Chikuma S, Kawaguchi Y, et al. Blockade of CD28/CTLA4-B7 pathway prevented autoantibody-related diseases but not lung disease in MRL/lpr mice. Lab Invest 1999;79:317-26. (Pubitemid 29166447)
28. Takiguchi M, Murakami M, Nakagawa I, Saito I, Hashimoto A, Uede T. CTLA4IgG gene delivery prevents autoantibody production and lupus nephritis in MRL/lpr mice. Life Sci 2000;66:991-1001. (Pubitemid 30090389)
29. Tieng AT, Peeva E. B-cell-directed therapies in systemic lupus erythematosus. Semin Arthritis Rheum 2008;38:218-27.
30. Arditti FD, Rabinkov A, Miron T, Reisner Y, Berrebi A, Wilchek M, et al. Apoptotic killing of B-chronic lymphocytic leukemia tumor cells by allicin generated in situ using a rituximab-alliinase conjugate. Mol Cancer Ther 2005;4:325-31. (Pubitemid 40340211)
31. Gall JM, Davol PA, Grabert RC, Deaver M, Lum LG. T cells armed with anti- CD3xanti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro. Exp Hematol 2005;33:452-9. (Pubitemid 40387628)
32. Garcia-Carrasco M, Jimenez-Hernandez M, Escarcega RO, Mendoza-Pinto C, Galarza-Maldonado C, Sandoval-Cruz M, et al. Use of rituximab in patients with systemic lupus erythematosus: an update. Autoimmun Rev 2009;8:343-8.
33. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002;46:2673-7. (Pubitemid 36118931)
34. Jonsdottir T, Gunnarsson I, Risselada A, Henriksson EW, Klareskog L, van Vollenhoven RF. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis 2008;67:330-4. (Pubitemid 351281266)
35. Weide R, Heymanns J, Pandorf A, Koppler H. Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus 2003;12:779-82. (Pubitemid 37295814)
36. Volpers C, Kochanek S. Adenoviral vectors for gene transfer and therapy. J Gene Med 2004;6(Suppl 1):S164-71.
37. Zhang S, Xu G, Liu C, Xiao S, Sun Y, Su X, et al. Clinical study of recombinant adenovirus-p53 (Adp53) combined with hyperthermia in advanced cancer (a report of 15 cases). Int J Hyperthermia 2005;21:631-6. (Pubitemid 41684237)
38. Wold WS, Tollefson AE, Hermiston TW. E3 transcription unit of adenovirus. Curr Top Microbiol Immunol 1995;199(Pt 1):237-74.
39. Sakurai F, Mizuguchi H, Yamaguchi T, Hayakawa T. Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector. Mol Ther 2003;8:813-21. (Pubitemid 37527457)
40. Imperiale MJ, Kochanek S. Adenovirus vectors: biology, design, and production. Curr Top Microbiol Immunol 2004;273:335-57. (Pubitemid 37203637)